Swiss biotech Actelion Pharmaceuticals Ltd. is not only trying to diversify its product portfolio away from pulmonary arterial hypertension (PAH), with Phase III drugs in multiple sclerosis (ponesimod) and Clostridium difficile infection (cadazolid), it is also “committed to remaining a leader in the pulmonary hypertension field,” according to CEO Jean-Paul Clozel.
Actelion's Opsumit Shows MERIT In CTEPH
The Switzerland-based biotech Actelion is bullish about new indications and labeling updates for its marketed pulmonary arterial hypertension product macitentan, including in CTEPH, and has also unveiled a promising Phase II candidate for resistant hypertension.
More from Respiratory
More from Therapy Areas
• By
Following the near-total dominance of IgG antibodies, the UK group is backing the potential of IgA and IgE-based therapies to transform cancer treatment with the purchase of US-headquartered TigaTx.
• By
By allowing it to enter the brain more easily, trontinemab’s brain shuttle brings more patients to ‘amyloid zero’ levels faster, and with fewer brain swelling side effects.
• By
BeiGene’s Phase III ociperlimab joins the list of failed TIGIT inhibitors, as candidates from Roche, Merck & Co. and others have failed late-stage studies.